Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare Biotechnology
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc
<< Previous
 Bullboard Posts
User Avatar Image
(7)
•••
  • Alex1726X
Comment by Alex1726on May 22, 2025 10:12am
95 Views
Post# 36582614

RE:FINS Review (3 / 5 stars)

RE:FINS Review (3 / 5 stars)Don't pay attention to this report, no mention of the out licensing deal fot natroba, that is a major catalyst. If you do your DD you'll see that PICLIDENOSON will be approved for psoriasis, 2 final phases III goes on. CFO has clearly mentionned during last conference call that cph intends to utilise Block purshase and i am sure they will. You have to keep in mind that Craig Mull has decided to move CPH'S share price higher anf HE WILL no matter what. 

The day they'll be happy with the share price and they'll decide that all majors and minors acquisitions has been completed they'll start paying a dividend. This day you can say stock has finished climbing. 
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities